Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Viking Therapeutics (VKTX) and Regeneron (REGN)

AI-generated analysis

🩺 Healthcare stocks Universal Health (UHS), Viking Therapeutics (VKTX), and Regeneron (REGN) received mixed analyst attention on Friday, May 1.

📈 Mizuho Securities analyst Ann Hynes maintained a Buy rating on Universal Health with a price target of $230, up from the stock's closing price of $167.97.

⭐ Analyst Ann Hynes holds a 4-star rating on TipRanks.com with an average return of 4.9% and a 54.8% success rate covering healthcare stocks.

🏥 Universal Health currently carries a Moderate Buy consensus with a $226.75 price target representing 41.7% upside from current levels.

💊 BTIG analyst Jeet Mukherjee maintained a Buy rating on Viking Therapeutics with a $125 price target while the stock closed near its 52-week low of $31.33.

🌟 Analyst Jeet Mukherjee is rated 4-stars on TipRanks.com with an average return of 12.4% and covers healthcare-focused biotechnology companies.

⚡ The street generally suggests a Strong Buy consensus for Viking Therapeutics with an average price target of $93.27 implying 188.9% upside.

🛑 Morgan Stanley analyst Terence Flynn maintained a Hold rating on Regeneron today with a price target of $788, though the stock closed near its low of $629.02.

⭐⭐⭐⚡ Analyst Terence Flynn holds a 5-star rating on TipRanks.com with an average return of 8.7% and a 55.6% success rate.

🧬 Regeneron currently has a Strong Buy consensus with a $875.95 price target, though analyst xAI downgraded it to Hold yesterday.

📉 Multiple analysts recently lowered their price targets for Universal Health, including Cantor Fitzgerald, TD Cowen, Guggenheim, and RBC Capital.

⚠️ The article includes disclaimers from the Globe and Mail noting that content is syndicated and potentially compensated placement.

Bullish Signals
  • Universal Health has a Strong Buy consensus from analysts with an average price target of $226.75, representing significant upside potential.
  • Analyst Ann Hynes from Mizuho Securities maintains a Buy rating on Universal Health with a price target of $230.00.
  • Viking Therapeutics boasts a Strong Buy consensus rating with an average price target of $93.27, implying nearly 189% upside from current levels.
  • Jeet Mukherjee from BTIG maintained a Buy rating on Viking Therapeutics with a price target of $125.00.
  • Regeneron holds a Strong Buy consensus rating with an average price target of $875.95, indicating 24.2% upside from current trading levels.
  • Morgan Stanley analyst Terence Flynn maintains a Hold rating on Regeneron with a price target of $788.00.
Risk Factors
  • Regeneron's stock price of $686.36 is trading near its 52-week low of $629.02, indicating significant downward momentum despite a Strong Buy consensus.
  • Morgan Stanley analyst Terence Flynn downgraded the outlook with a Hold rating and lowered the price target to $788.00, signaling diminished bullish sentiment from major institutional players.
  • TipRanks – xAI recently issued a downgrade on Regeneron, setting a more conservative price target of $798.00 which contradicts the broader Strong Buy consensus.
  • There is no clear positive catalyst to counter the downward pressure as highlighted by the proximity to recent lows and mixed analyst actions.
  • Universal Health faces headwinds as evidenced by multiple analyst firms lowering their price targets in recent weeks, with Cantor Fitzgerald, TD Cowen, Guggenheim, and RBC Capital all reducing their valuations.
Full Analysis
Analysts have presented mixed opinions regarding three major healthcare stocks: Universal Health Services (UHS), Viking Therapeutics (VKTX), and Regeneron Pharmaceuticals (REGN). For Universal Health, Mizuho Securities analyst Ann Hynes maintained a Buy rating with a price target of $230.00, while the stock's shares closed last Wednesday at $167.97. Although Hynes is noted as a 4-star analyst with an average return of 4.9% and a 54.8% success rate, other analysts have adjusted their targets downward; Cantor Fitzgerald lowered its target to $194 from $229, TD Cowen reduced it to $230 from $245, Guggenheim set it at $211 from $238, and RBC Capital dropped its estimate to $190 from $216. Despite these varied opinions, the analyst consensus for Universal Health remains a Moderate Buy with an average price target of $226.75, representing a 41.7% upside from current levels. TipRanks previously noted that DeepSeek upgraded the stock to Buy with a $199.00 target on April 24. Viking Therapeutics has received strong support, particularly from BTIG analyst Jeet Mukherjee, who maintained a Buy rating with a price target of $125.00 after the company's shares closed at $31.33, near its 52-week low of $24.41. Mukherjee is rated a 4-star analyst with an average return of 12.4% and a 43.6% success rate, covering other healthcare entities such as Ascentage Pharma Group International. The general market sentiment suggests a Strong Buy consensus for Viking Therapeutics, reflecting an average price target of $93.27 that implies a substantial 188.9% upside from current pricing. Additionally, William Blair recently maintained its Buy rating on the stock, reinforcing positive analyst coverage despite the stock's proximity to recent lows. In contrast, Regeneron Pharmaceuticals faces a divided outlook following comments today by Morgan Stanley analyst Terence Flynn. Flynn assigned a Hold rating to REGN and set a price target of $788.00 for shares that closed at $686.36, which is close to its 52-week low of $629.02. Flynn holds the status of a 5-star analyst with an average return of 8.7% and a 55.6% success rate, frequently covering peers like Vertex Pharmaceuticals. However, the broader analyst consensus for Regeneron remains a Strong Buy with an average price target of $875.95, indicating a 24.2% upside potential. Despite this general bullishness, TipRanks – xAI downgraded Regeneron to Hold with a $798.00 target yesterday, highlighting the conflicting signals surrounding the biotechnology giant.